MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Piccart, M.
Borrego, M. Ruiz
Arkenau, H-T.
Escriva-De-Romani, S. I.
Howell, S. J.
Hennequin, A.
Jimenez-Rodriguez, B.
Del Conte, G.
Simonelli, M.
Palleschi, M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
